Skip to main content
H.R. 5629 119th Congress House

To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to…

Official title: To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the por… Show full official titleShow less

Official title: To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.

Introduced: September 30, 2025 Introduced by: Erin Houchin Republican · Indiana See on congress.gov
Health
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 30, 2025
Referred to the House Committee on Energy and Commerce.
Sep 30, 2025
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now September 30, 2025

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

This bill nullifies part of the final rule issued by the Department of Health and Human Services (HHS) titled Medications for the Treatment of Opioid Use Disorder and published on February 2, 2024.

The rule incorporated into regulations certain flexibilities for opioid treatment that were initially implemented during the COVID-19 public health emergency. The bill nullifies these flexibilities, including (1) expanded flexibility for patients in their first or second month of treatment to receive take-home doses of methadone, (2) flexibility to use telehealth examinations to admit patients for treatment involving buprenorphine or methadone, and (3) expanded access to evidence-based practices such as splitting doses for certain patients. 

Pursuant to a statutory requirement, the rule also allowed patients to be admitted to an opioid treatment program without having to show at least a one-year history of opioid misuse. The bill nullifies these provisions of the rule.

 Hearings & markups 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 35

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 35 filings →
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5629: To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.. 119th Congress. Open America. https://openamerica.io/bill/119-HR-5629/
MLA
"H.R. 5629: To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-5629/.
Bluebook (legal)
H.R. 5629, 119th Cong. (2026), https://openamerica.io/bill/119-HR-5629/.
Markdown link
[H.R. 5629: To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.](https://openamerica.io/bill/119-HR-5629/)
Report a problem